HF
RCUS icon

HRT Financial’s Arcus Biosciences RCUS Stock Holding History

HRT Financial’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-89,997
Closed -$1.22M – 3883
2025
Q3 		$1.22M Buy
+89,997
New +$936K ﹤0.01% 1425
2024
Q3 		– Sell
-46,579
Closed -$709K – 3008
2024
Q2 		$709K Buy
+46,579
New +$752K ﹤0.01% 1152
2024
Q1 		– Sell
-95,819
Closed -$1.83M – 2954
2023
Q4 		$1.83M Buy
+95,819
New +$1.53M 0.01% 688
2023
Q1 		– Sell
-124,820
Closed -$2.58M – 3069
2022
Q4 		$2.58M Buy
+124,820
New +$3.43M 0.04% 480
2022
Q3 		– Sell
-34,674
Closed -$878K – 3372
2022
Q2 		$878K Buy
+34,674
New +$849K 0.01% 1044
2021
Q1 		– Sell
-11,652
Closed -$302K – 3072
2020
Q4 		$302K Buy
+11,652
New +$282K 0.01% 1281

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

HRT Financial's RCUS Position: Q4 2025 in Review

HRT Financial sold out of Arcus Biosciences (RCUS) in Q4 2025, closing a stake of 89,997 shares — an estimated $1.22M sold.

HRT Financial first reported a position in RCUS in Q4 2020 and held it in 6 quarters. The position peaked at $2.58M in Q4 2022. 209 funds tracked by Wall St. Rank hold RCUS as of Q4 2025.

  • HRT Financial reported no remaining Arcus Biosciences position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 89,997 Arcus Biosciences shares in Q4 2025, an estimated $1.22M.
  • HRT Financial first reported a position in Arcus Biosciences in Q4 2020 and held it in 6 quarters.
  • HRT Financial's Arcus Biosciences position peaked at $2.58M in Q4 2022.
  • 209 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.